T cell retargeting with MHC class I-restricted antibodies: The CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production

Journal of Immunology

Volumn 174, Issue 12, 2005, Pages 7853-7858

  Willemsen, Ralph A ^a   Ronteltap, Cees ^a   Chames, Patrick ^b   Debets, Reno ^a   Bolhuis, Reinder L H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Arvid Wallgrens Backe 20   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; CD28 ANTIGEN; CHIMERIC ANTIBODY; FC RECEPTOR; GAMMA INTERFERON; HLA A1 ANTIGEN; HLA B7 ANTIGEN; HYB3 ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT G8; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 1; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN SPECIFIC CYTOTOXICITY; ANTIGEN SPECIFICITY; ARTICLE; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA CELL; NORMAL HUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RECEPTOR BINDING; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL;

EID: 20444377728     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.12.7853     Document Type: Article

References (46)

1. McKenzie, I. F., V. Apostolopoulos, M. Plebanski, G. A. Píetersz, and B. E. Loveland. 2003. Aspects of cancer immunotherapy. Immunol. Cell Biol. 1: 79-85.
2. Renkvist, N., C. Castelli, P. F. Robbins, and G. Parmiani. 2001. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50: 3-15.
3. Rosenberg, S. A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18: 175-184.
4. Kuwana, Y., Y. Asakura, N. Utsunomiya, M. Nakanishi, Y. Arata, S. Itoh, F. Nagase, and Y. Kurosawa. 1987. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem. Biophys. Res. Commun. 149: 960-968.
5. Gross, G., and Z. Eshhar. 1992. Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J. 6: 3370-3378.
6. Eshhar, Z., T. Waks, G. Gross, and D. G. Schindler. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody binding domains and the γ or ζ subunits of the immunoglobulin and T cell receptors. Proc. Natl. Acad. Sci. USA 90: 720-724.
7. Nolan, K. F., C. O. Yun, Y. Akamatsu, J. C. Murphy, S. O. Leung, E. J. Beecham, and R. P. Junghans. 1999. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin. Cancer Res. 5: 3928-3941.
8. Moritz, D., W. Wels, J. Mattern, and B. Groner. 1994. Cytotoxic T lymphocytes with grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl. Acad. Sci. USA 91: 4318-4322.
9. Hombach, A., C. Heuser, R. Sircar, T. Tillmann, V. Diehl, C. Pohl, and H. Abken. 1998. An anti-CD30 chimeric receptor that mediates CD3-ζ- independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res. 58: 1116-1119.
10. Weijtens, M. E. M., R. A. Willemsen, D. Valerio, K. Stam, and R. L. H. Bolhuis. 1996. Single chain Ig/γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J. Immunol. 157: 836-843.
11. Clay, T. M., M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura. 1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163: 507-513.
12. Willemsen, R. A., M. E. Weijtens, C. Ronteltap, Z. Eshhar, J. W. Gratama, P. Chames, and R. L. Bolhuis. 2000. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther. 7: 1369-1377.
13. Cooper, L. J., M. Kalos, D. A. Lewinsohn, S. R. Riddell, and P. D. Greenberg. 2000. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74: 8207-8212.
14. Heemskerk, M. H., R. A. de Paus, E. G. Lurvink, F. Koning, A. Mulder, R. Willemze, J. J. van Rood, and J. H. Falkenburg. 2001. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc. Natl. Acad. Sci. USA 98: 6806-6811.
15. Stanislawski, T., R. H. Voss, C. Lotz, E. Sadovnikova, R. A. Willemsen, J. Kuball, T. Ruppert, R. L. Bolhuis, C. J. Melief, C. Huber, et al. 2001. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2: 962-970.
16. Schaft, N., R. Willemsen, J. de Vries, B. Lankiewicz, B. Esser, J.-W. Gratama, C. Figdor, R. Bolhuis, R. Debets, and G. Adama. 2003. Peptide fine-specificity of anti-gp 100 CTL is preserved following transfer of engineered TCRα/β genes into primary human T lymphocytes. J. Immunol. 170: 2186-2194.
17. Machiels, J. P., N. van Baren, and M. Marchand. 2002. Peptide-based cancer vaccines. Semin. Oncol 29: 494-502.
18. Parmiani, G., C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini. 2002. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94: 805-818.
19. Rosenberg, S. A., B. S. Packard, P. M Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N. Engl. J. Med. 319: 1676-1680.
20. Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J. Cancer Inst. 86: 1159-1166.
21. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
22. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
23. Willemsen, R. A., R. Debets, E. H. Hart, H. R. Hoogenboom, R. L. H. Bolhuis, and P. Chames. 2001. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther. 8: 1601-1608.
24. Chames, P., R. A. Willemsen, G. Rojas, D. Dieckmann, L. Rem, G. Schuler, R. L. Bolhuis, and H. R. Hoogenboom. 2002. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J. Immunol. 169: 1110-1118.
25. Van de Griend, R. J., B. A. Van Krimpen, S. J. L. Bol, A. Thompson, and R. L. H. Bolhuis. 1984. Rapid expansion of human cytotoxic T cell clones: growth promotion by a heat-labile serum component and by various types of feeder cells. J. Immunol. Methods 66: 285-298.
26. Soneoka, Y., P. M. Cannon, E. E. Ramsdale, J. C. Griffiths, G. Romano, S. M. Kingsman, and A. J. Kingsman. 1995. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 23: 628-633.
27. Grignani, F., T. Kinsella, A. Mencarelli, M. Valtieri, D. Riganelli, F. Grignani, L. Lanfrancone, C. Peschle, G. P. Nolan, and P. G. Pelicci. 1998. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res. 58: 14-19.
28. Weijtens, M. E. M., R. A. Willemsen, E. H. Hart, and R. L. H. Bolhuis, 1998. A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther. 5: 1195-1203.
29. Haynes, N. M., J. A. Trapani, M. W. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy. 2002. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J. Immunol. 169: 5780-5786.
30. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
31. Schultze, J., L. M. Nadler, and J. G. Gribben. 1996. B7-mediated costimulation and the immune response. Blood Rev. 10: 111-127.
32. Maher, J., R. J. Brentjens, G. Gunset, I. Riviere, and M. Sadelain. 2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat. Biotechnol 20: 70-75.
33. Geiger, T. L., P. Nguyen, D. Leitenberg, and R. A. Flavell. 2001. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 98: 2364-2371.
34. Eshhar, Z., T. Waks, A. Bendavid, and D. G. Schindler. 2001. Functional expression of chimeric receptor genes in human T cells. J. Immunol. Methods 248: 67-76.
35. Haynes, N. M., J. A. Trapani, M. W. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy. 2002. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100: 3155-3163.
36. Beecham, E. J., Q. Ma, R. Ripley, and R. P. Junghans. 2000. Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death. J. Immunother. 23: 631-642.
37. Pinthus, J. H., T. Waks, K. Kaufman-Francis, D. G. Schindler, A. Harmelin, H. Kanety, J. Ramon, and Z. Eshhar. 2003. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 63: 2470-2476.
38. Finney, H. M., A. D. Lawson, C. R. Bebbington, and A. N. Weir. 1998. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161: 2791-2797.
39. Krause, A., H. F. Guo, J. B. Latouche, C. Tan, N. K. Cheung, and M. Sadelain. 1998. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188: 619-626.
40. Alvarez-Vallina. L., and R. A. Hawkins. 1996. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur. J. Immunol 26: 2304-2309.
41. Hombach, A., D. Sent, C. Schneider, C. Heuser, D. Koch, C. Fohl, B. Seliger, and H. Abken. 2001. T-cell activation by recombinant receptors: CD28 cosumulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res. 61: 1976-1982.
42. Hombach, A., A. Wieczarkowiecz, T. Marquardt, C. Heuser, L. Usai, C. Pohl, B. Seliger, and H. Abken. 2001. Tumor-specific T cell activation by recombinant Immunoreceptors: CD3 ζ signaling and CD28 costimulation are simultaneously required for efficient TL-2 secretion and can be integrated into one combined CD28/CD3 ζ signaling receptor molecule. [Published erratum appears in 2004 J. Immunol. 173: 695] J. Immunol. 167: 6123-6131.
43. Abken, H., A. Hombach, C. Heuser, K. Kronfeld, and B. Seliger. 2002. Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol. 23: 240-245.
44. Riddell, S. R., and P. D. Greenberg. 2000. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J. Antimicrob. Chemother. 45: 35-43.
45. McKeithan, T. W. 1995. Kinetic proofreading in T-cell receptor signal transduction. Proc. Natl. Acad. Sci. USA 92: 5042-5046.
46. Chames, P., S. E. Hufton, P. G. Coulie, B. Uchanska-Ziegler, and H. R. Hoogenboom. 2000. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc. Natl. Acad. Sci. USA 97: 7969-7974.